<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058730</url>
  </required_header>
  <id_info>
    <org_study_id>MAMBS04</org_study_id>
    <nct_id>NCT04058730</nct_id>
  </id_info>
  <brief_title>Comparative Interventional Study to Evaluate the Role of LRYGBP, LSG &amp; SMM</brief_title>
  <official_title>A Comparative Interventional Study to Evaluate the Role of LRYGBP, LSG and SMM in Patients of Type II DM and BMI Between 27.5 - 32.5 kg / m².&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Institute of Minimally Access, Metabolic &amp; Bariatric Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Max Institute of Minimally Access, Metabolic &amp; Bariatric Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Comparative Interventional Study to Evaluate the Role of Laparoscopic Roux-en-Y Gastric&#xD;
      Bypass (LRYGBP), Laparoscopic Sleeve Gastrectomy (LSG) and Standard Medical Management (SMM)&#xD;
      in Patients of Type II Diabetes Mellitus (DM) and Body Mass Index ( BMI) Between 27.5 - 32.5&#xD;
      kg / m².&quot;&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to evaluate the role of Laparoscopic Roux-en-Y Gastric&#xD;
      bypass(LRYGBP), Laparoscopic Sleeve Gastrectomy (LSG) and Standard medical management in&#xD;
      patients of type II diabetes and BMI between 27.5 - 32.5 kg / m².&quot;&#xD;
&#xD;
        -  A. Partial Remission&#xD;
&#xD;
        -  B. Complete Remission&#xD;
&#xD;
        -  C. No Remission&#xD;
&#xD;
      Secondary Objective is to evaluate the role of LRYGB, LSG and SMM on other metabolic disorder&#xD;
      parameters like&#xD;
&#xD;
        -  Dyslipidemia&#xD;
&#xD;
        -  Hypertension&#xD;
&#xD;
        -  Waist Circumference&#xD;
&#xD;
      This is a study comparing the role of LRYGB, LSG and SMM in subjects suffering from Type II&#xD;
      diabetes mellitus with BMI between 27.5 - 32.5 kg/m². Diabetic patients shall be enrolled as&#xD;
      per the inclusion and exclusion criteria. The study treatment will be LRYGB surgery or LSG or&#xD;
      SMM in subjects who qualify the inclusion/ exclusion criteria.&#xD;
&#xD;
      Post discharge the study subjects will be followed up at the following intervals:&#xD;
&#xD;
      1 Month, 3 Months 12 Months and 24 Months respectively At follow up subjects shall have an&#xD;
      overall clinical examination, adverse events and complication shall be recorded and blood&#xD;
      samples for laboratory investigation shall be collected.&#xD;
&#xD;
      Number of Subjects&#xD;
&#xD;
      Planned: 150 qualified subjects&#xD;
&#xD;
      To be Analyzed: 150 qualified subjects&#xD;
&#xD;
      Statistical Methods:&#xD;
&#xD;
      Study Population Male and female subjects 30-60 years of age with Type II Diabetes and BMI&#xD;
      between 27.5 - 32.5 kg/m2, who fulfill all the inclusion criteria and do not meet any&#xD;
      exclusion criteria will be enrolled into the Study.&#xD;
&#xD;
      Sample Size In this study 150 eligible subjects will be enrolled. One Fifty subjects enrolled&#xD;
      would provide the 95% of confidence interval with 10% absolute precision.&#xD;
&#xD;
      Statistical Analysis In this study first normality of the data will be checked. Normally&#xD;
      distributed data will be analysed by paired t-test. For non- parametric data Wilcox-on signed&#xD;
      rank sum test will be used.&#xD;
&#xD;
      As same Subject will be examined at different time points (more than two time points) the&#xD;
      ANOVA of Repeated measures will be used. All tests will be two-tailed and the significance&#xD;
      level will be 0.05&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Haemoglobin less than 6.5 mg/dl</measure>
    <time_frame>immediately after the surgery upto 2 years</time_frame>
    <description>The remission of Type II Diabetes Mellitus will be assessed on the basis of the Glycosylated Haemoglobin levels of the patient post surgery.. At 1 month, 3months, 12months, 24 months after discharge</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>LRYGBP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic Roux en Y Gastric by pass surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic RYGB is primarily a restrictive procedure with a small element of malabsorption.&#xD;
Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LSG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laparoscopic Sleeve Gastrectomy surgery will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Laparoscopic Sleeve Gastrectomy is a pure restrictive procedure. Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients to evaluate the effect of the intervention at 1 month, 3 months, 12 months and 24 months post discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard Medical Management will be evaluated for patients of Type II DM with BMI between 27.5-32.5 kg/m2 Standard Medical management will be as per the recommendation of ADA 2010 guidelines.&#xD;
Glycosylated Haemoglobin will be used as a parameter to assess the status of Type II Diabetes for these patients 1 month, 3 months, 12 months and 24 months post consult</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Roux en Y Gastric by pass surgery</intervention_name>
    <arm_group_label>LRYGBP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Sleeve Surgery</intervention_name>
    <arm_group_label>LSG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Management</intervention_name>
    <arm_group_label>SMM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 30 to 60 years at the time of enrollment.&#xD;
&#xD;
          -  Type II DM present according to standard diagnostic criteria (ADA 2010) for at least 6&#xD;
             months.&#xD;
&#xD;
          -  Body mass Index (BMI) between 27.5 - 32.5 kg / m².&#xD;
&#xD;
          -  Waist circumference&gt;90 cm if male; &gt;80cm if female.&#xD;
&#xD;
          -  Demonstrated to have inadequate control of diabetes defined as HbA1c &gt;8.0mg/dl&#xD;
&#xD;
          -  Patients who have given written informed consent.&#xD;
&#xD;
          -  Ability to complete the run in for dietary intake and exercise&#xD;
&#xD;
          -  Willingness and ability to comply with the follow up protocol, including returns to&#xD;
             the clinical center for visits at 1, 3, 12, 24, months post surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TypeII DM of more than 10 years duration.&#xD;
&#xD;
          -  Weight loss of more than 9Kgs in preceding six months.&#xD;
&#xD;
          -  Currently pregnant or planning to become pregnant.&#xD;
&#xD;
          -  Cancer requiring treatment in the past 5 years&#xD;
&#xD;
          -  Active HIV or tuberculosis&#xD;
&#xD;
          -  CVD event within 6 months prior to enrollment&#xD;
&#xD;
          -  Pulmonary embolus in past 6 months&#xD;
&#xD;
          -  CVD manifesting any of the following criteria: unstable angina pectoris or angina&#xD;
             pectoris at rest; a history of cardiac arrest; complex ventricular arrhythmia at rest&#xD;
             or with exercise; uncontrolled atrial fibrillation(heart rate of 100 beats per minute&#xD;
             or more); New York Heart Association Class III or IV congestive her failure; acute&#xD;
             myocarditis, pericarditis or hypertrophic myocardiopathy; clinically significant&#xD;
             aortic stenosis; left bundle block or cardiac pace maker unless approved by&#xD;
             cardiologist, cardiac defibrillator; history of aortic aneurysum or at least 7cm in&#xD;
             diameter or aortic aneurysum repair; resting heat rate&lt;45 beats per minute or &gt;100&#xD;
             beats per minute; heart transplantation.&#xD;
&#xD;
          -  Serum creatinine &gt;1.4mg/dl(women) or 1.5mg/dl(men)&#xD;
&#xD;
          -  History of PE or DVT within 6 months&#xD;
&#xD;
          -  Abnormal serum free T4 (&gt;1.8) of thryrotropin (TSH &gt;5.5)&#xD;
&#xD;
          -  Bilirubin, aspartate amino transferase (AST) or alkaline phosphatase more than thrice&#xD;
             the normal.&#xD;
&#xD;
          -  Hospitalization for depression in past 6 months.&#xD;
&#xD;
          -  Travel plans that inhibits full participation&#xD;
&#xD;
          -  History of bariatric surgery, small bowel resection or extensive large bowel resection&#xD;
&#xD;
          -  Chronic treatment with systematic corticosteroids&#xD;
&#xD;
          -  Current diagnosis of schizophrenia, or other psychotic disorder, bipolar disorder,&#xD;
             alcohol abuse or substance abuse.&#xD;
&#xD;
          -  Alcoholic or drug addict ( daily consumption of alcohol &gt;60ml in males and &gt;30ml in&#xD;
             females)&#xD;
&#xD;
          -  Unstable proliferative retinopathy&#xD;
&#xD;
          -  Other medical, psychiatric, or behavioral limitations that in the judgments of the&#xD;
             investigators may interfere with study participation or the ability to follow the&#xD;
             intervention protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Max Institute of Minimal Access Metabolic and Bariatric Surgery</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Max Institute of Minimal Access, Metabolic &amp; Bariatric Surgery</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2018</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Max Institute of Minimally Access, Metabolic &amp; Bariatric Surgery</investigator_affiliation>
    <investigator_full_name>DR PRADEEP CHOWBEY</investigator_full_name>
    <investigator_title>Chairman- Max Institute of Minimal Access, Metabolic and Bariatric Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

